Find the right fit for you - faster
Get tailored insights about working at Zephyr Sleep Technologies in one quick step.
Zephyr Sleep Technologies Snapshot
View siteWebsite
Company Background
Zephyr Sleep Technologies (“ZST” or the “Company”) designs, develops and manufactures medical devices for diagnosis and treatment of sleep disordered breathing. Zephyr has launched its second generation product, the MATRx Plus, designed to fulfill the needs of a significant and expanding market in the US. The MATRx Plus is a tablet-based and cloud-connected medical device designed to be used at the patient’s home and is currently cleared by Health Canada for sale in Canada and by the US Food and Drug Administration (FDA) for sale in the US. The MATRx Plus medical device is used to complete a two-night home study which determines: i) If a simple oral appliance is capable of treating obstructive sleep apnea (“OSA”,; and, ii) a therapeutic position for the mandible. This information allows a dentist to custom make an oral appliance for an OSA patient.
Zephyr Sleep Technologies was founded in 2010 principally by Paul Cataford (CEO), John Remmers (Chief Medical Officer) and Sabina Bruehlmann (Director – Technology) and was spun out of the University of Calgary. Zephyr is a private company headquartered in Calgary Alberta with 36 employees. The intent is to grow the team to 55 by the end of 2019 Since inception, the Company has raised over $17 million - $6.7 million from investors and over $10 million from non-dilutive sources (government & strategic partners).
Partnership with DENTSPLY SIRONA (“D/S”)
On June 30, 2017 ZST closed a strategic investment with Dentsply Sirona (“D/S”), the largest dental technology company in the world. In addition to the investment, D/S is also “bundling” a MATRx Plus with each of its 3D AI – cone beam CT scanners in the US.
Traction
The MATRx is installed in 200 sleep labs and clinics in NA and over 12,000 tests have been completed since 2013. MATRx users include Kaiser Permenante in northern CA. The MATRx Plus has cleared Health Canada since the beginning of the year and is installed in close to 50 sites so far in Canada. The Company is now cleared by the FDA to sell the MATRx Plus in the US and has backlog of over $1 million. The plan is to be in 3,000-5,000 dentist offices by the end of 2020 bringing in annual revenues in excess of $35 million.
Our Mission: Making it simple.
Zephyr Sleep Technologies (“ZST” or the “Company”) designs, develops and manufactures medical devices for diagnosis and treatment of sleep disordered breathing. Zephyr has launched its second generation product, the MATRx Plus, designed to fulfill the needs of a significant and expanding market in the US. The MATRx Plus is a tablet-based and cloud-connected medical device designed to be used at the patient’s home and is currently cleared by Health Canada for sale in Canada and by the US Food and Drug Administration (FDA) for sale in the US. The MATRx Plus medical device is used to complete a two-night home study which determines: i) If a simple oral appliance is capable of treating obstructive sleep apnea (“OSA”,; and, ii) a therapeutic position for the mandible. This information allows a dentist to custom make an oral appliance for an OSA patient.
Zephyr Sleep Technologies was founded in 2010 principally by Paul Cataford (CEO), John Remmers (Chief Medical Officer) and Sabina Bruehlmann (Director – Technology) and was spun out of the University of Calgary. Zephyr is a private company headquartered in Calgary Alberta with 36 employees. The intent is to grow the team to 55 by the end of 2019 Since inception, the Company has raised over $17 million - $6.7 million from investors and over $10 million from non-dilutive sources (government & strategic partners).
Partnership with DENTSPLY SIRONA (“D/S”)
On June 30, 2017 ZST closed a strategic investment with Dentsply Sirona (“D/S”), the largest dental technology company in the world. In addition to the investment, D/S is also “bundling” a MATRx Plus with each of its 3D AI – cone beam CT scanners in the US.
Traction
The MATRx is installed in 200 sleep labs and clinics in NA and over 12,000 tests have been completed since 2013. MATRx users include Kaiser Permenante in northern CA. The MATRx Plus has cleared Health Canada since the beginning of the year and is installed in close to 50 sites so far in Canada. The Company is now cleared by the FDA to sell the MATRx Plus in the US and has backlog of over $1 million. The plan is to be in 3,000-5,000 dentist offices by the end of 2020 bringing in annual revenues in excess of $35 million.
Our Mission: Making it simple.
